GlaxoSmithKline (LON:GSK) Rating Reaffirmed
GlaxoSmithKline (LON:GSK) just had their share rating of a ‘”Hold”‘ issued by research analysts at Jefferies, who now has a GBX 1325 target price on the 64.18 billion GBP market cap company or a -0.64% downside potential. This key information was disclosed in a very recent research note on 7 December.
From a total of 24 analysts covering GlaxoSmithKline PLC (LON:GSK) stock, 6 rate it a ”Buy”, 4 a “Sell”, and 20 a ”Hold”. This means that 20% of the ratings are positive. The highest target price is GBX 1800 while the lowest target price is GBX 1250. The mean of all analyst targets is GBX 1470.25 with a 10.37% above today’s (GBX 1335) stock price. GlaxoSmithKline PLC was the topic of 94 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. Jefferies maintained shares on December 7 with “Hold” rating. J.P. Morgan maintained shares with “Neutral” rating and GBX 1370 target share price in a report from a November 20. Morgan Stanley maintained GSK stock in a recent report from December 2 with “Equal-Weight” rating. JP Morgan maintained the rating on November 17. JP Morgan has a “Neutral” rating and a GBX 1370 price target on shares. Finally, Goldman Sachs maintained the stock with “Buy” rating in a report issued on a November 24.
Approximately 1.17M shares of stock traded hands. GlaxoSmithKline plc (LON:GSK) has declined 10.79% since May 8, 2015 and is downtrending. It has underperformed by 9.71% the S&P500.
GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 64.18 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.57 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.
According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.” Get a free copy of the Zacks research report on GlaxoSmithKline plc (GSK).